You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

Claims for Patent: 9,808,530

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,808,530

Title:	Composition of tiacumicin compounds
Abstract:	A composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof, in combination with an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof is provided. Further, use of an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof as an anti-foaming agent in a composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof is provided.
Inventor(s):	Murakami; Yoshiyuki (Tokyo, JP), Saito; Hikaru (Tokyo, JP)
Assignee:	Astellas Pharma Europe Ltd. (Chertsey, Surrey, GB)
Application Number:	14/766,904
Patent Claims:	1. A pharmaceutical composition comprising as the active ingredient a tiacumicin B compound, analogues thereof, a stereo-isomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof, and xanthan gum as an excipient, wherein the excipient is present in an amount to prevent foaming of the tiacumicin B compound in water. 2. The composition according to claim 1, wherein the active ingredient is fidaxomicin. 3. The composition according to claim 1, wherein the composition further contains microcrystalline cellulose or a sugar. 4. The composition according to claim 3, wherein the sugar is selected from the group consisting of D-mannitol, erythritol, isomalt and trehalose. 5. The composition according to claim 1, wherein the composition further contains one or more of a disintegrant. 6. The composition according to claim 1, wherein the composition further contains sodium starch glycolate. 7. The composition according to claim 1, wherein the composition further contains partially pregelatinised starch. 8. The composition according to claim 1, wherein the composition is in the form of a dry powder for an aqueous suspension, a dry granulate for an aqueous suspension or a dispersible tablet for an aqueous suspension. 9. The composition of claim 1, wherein the analogue of tiacumicin B is selected from the group consisting of dialkyltiacumicins and bromotiacumicins. 10. The composition of claim 1, wherein the pharmaceutical composition is an oral pharmaceutical composition.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.